Literature DB >> 1721837

Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein.

A Moreno1, P Clavijo, R Edelman, J Davis, M Sztein, D Herrington, E Nardin.   

Abstract

The present data provide the first evidence that a protozoan parasite, Plasmodium falciparum, can induce CD4+ cytotoxic T cells in man. The CD4+ cytotoxic T lymphocytes (CTL) were derived from a sporozoite-immunized volunteer who was protected against challenge with P. falciparum sporozoites. These T cells recognize an epitope within the circumsporozoite (CS) protein, an immunodominant sporozoite surface antigen, present also in liver stages of the parasite, which has been investigated as a vaccine candidate. The class II restricted T cell clones specifically lyse autologous B cells pulsed with a synthetic peptide representing a C-terminal sequence of the P. falciparum CS protein. The same peptide, as well as recombinant or native CS protein, also stimulates proliferation and gamma-interferon production by the CD4+ CTL. The CTL epitope, KIQNSLSTEW, is recognized in the context of HLA-DR7 and overlaps both a highly conserved, as well as a polymorphic, region of the P. falciparum CS protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721837     DOI: 10.1093/intimm/3.10.997

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  22 in total

1.  Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Daniel Feldman; Fen Yu; Kemp B Cease
Journal:  Vaccine       Date:  2014-11-30       Impact factor: 3.641

2.  A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.

Authors:  A Birkett; K Lyons; A Schmidt; D Boyd; G A Oliveira; A Siddique; R Nussenzweig; J M Calvo-Calle; E Nardin
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 3.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

Review 4.  Live attenuated pre-erythrocytic malaria vaccines.

Authors:  Gladys J Keitany; Marissa Vignali; Ruobing Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

Review 6.  A retrospective evaluation of the role of T cells in the development of malaria vaccine.

Authors:  Moriya Tsuji
Journal:  Exp Parasitol       Date:  2009-11-26       Impact factor: 2.011

7.  Class II-restricted protective immunity induced by malaria sporozoites.

Authors:  Giane A Oliveira; Kota Arun Kumar; J Mauricio Calvo-Calle; Caroline Othoro; David Altszuler; Victor Nussenzweig; Elizabeth H Nardin
Journal:  Infect Immun       Date:  2007-12-26       Impact factor: 3.441

Review 8.  Malaria vaccine development.

Authors:  T R Jones; S L Hoffman
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

9.  Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.

Authors:  Luciana M Silva-Flannery; Monica Cabrera-Mora; Jianlin Jiang; Alberto Moreno
Journal:  Microbes Infect       Date:  2008-10-26       Impact factor: 2.700

Review 10.  Pre-erythrocytic malaria vaccines: identifying the targets.

Authors:  Patrick E Duffy; Tejram Sahu; Adovi Akue; Neta Milman; Charles Anderson
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.